| scholarly article | Q13442814 |
| P2093 | author name string | Yasuhide Yamada | |
| Yutaka Fujiwara | |||
| Kazuhiko Yamada | |||
| Noboru Yamamoto | |||
| Tomohide Tamura | |||
| Yasuhito Fujisaka | |||
| Toshio Shimizu | |||
| P2860 | cites work | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 |
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product | Q28256232 | ||
| Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group | Q33349006 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| A potential role for activated HER-2 in prostate cancer. | Q34173125 | ||
| The EGF receptor family as targets for cancer therapy | Q34293543 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies | Q34599824 | ||
| Trastuzumab-associated cardiotoxicity | Q34867708 | ||
| The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis | Q34986549 | ||
| The ErbB receptors and their role in cancer progression. | Q35089324 | ||
| Experience with bevacizumab in the management of epithelial ovarian cancer | Q36873062 | ||
| Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. | Q40533899 | ||
| Characteristics of EGFR family-mediated HRG signals in human ovarian cancer | Q40891574 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis | Q46242920 | ||
| Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. | Q51776233 | ||
| Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2 | Q77124890 | ||
| Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab | Q81190157 | ||
| Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer | Q81378656 | ||
| P433 | issue | 4 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pertuzumab | Q1998021 | ||
| P304 | page(s) | 260-266 | |
| P577 | publication date | 2009-03-04 | |
| P1433 | published in | Japanese Journal of Clinical Oncology | Q2231629 |
| P1476 | title | Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors | |
| P478 | volume | 39 |
| Q38364462 | Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs |
| Q38119307 | Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab |
| Q37970020 | ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective |
| Q28237833 | HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer |
| Q38067454 | Monoclonal antibodies in lung cancer |
| Q30376023 | Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me |
| Q38219674 | Pertuzumab for the treatment of breast cancer |
| Q38776876 | Pertuzumab for the treatment of breast cancer: a safety review |
| Q38132527 | Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer |
| Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
| Q36336483 | Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan |
| Q37205749 | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer |
| Q33618685 | Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival |
| Q38286163 | Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q33680109 | Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations |
| Q38373931 | Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer |
| Q38126859 | Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer |
| Q38132047 | Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer |
| Q37982433 | Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer |
| Q38036549 | Pertuzumab: new hope for patients with HER2-positive breast cancer |
| Q37639279 | Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer |
| Q38573858 | Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy |
| Q28083123 | Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates |
| Q33714388 | Safety and efficacy evaluation of pertuzumab in patients with solid tumors |
| Q38123762 | Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer |
Search more.